Market Movers (8-K)
NASDAQ
Conexeu Sciences announced the completion of its 12-month P.R.O.O.F preclinical study for its CXU platform, demonstrating tissue restoration and injectable performance, paving the way for a planned 510(k) submission in wound care by Q1 2027.
Schedule 13D - Activist Investments
NASDAQ
Jeffrey Sharpe has increased his beneficial ownership in Conexeu Sciences Inc. to 5.4% following the vesting of performance warrants tied to market capitalization milestones.
Schedule 13G - Passive Investments
NASDAQ
David Bogart has filed a Schedule 13G, reporting beneficial ownership of 2,293,750 shares, representing 8.1% of Conexeu Sciences Inc.'s common stock.
NASDAQ
Michael G. Wright has reported beneficial ownership of 12.1% of Conexeu Sciences Inc. common stock as of June 30, 2026.
NASDAQ
Paisley Capital Holdings Corp. has reported beneficial ownership of 1,800,000 shares, representing 6.7% of the common stock of Conexeu Sciences Inc.